Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 801–850 of 77110
each of Bruno Bowden, Jason Mudrick, Neil Salvage, Qais Sharif and Sam Zaid, consisting of all of the members of the Company’s Board of Directors (the “Board”), has resigned from the Board
elected Mr. Jalbert as the sole member of the Board
each of Bruno Bowden, Jason Mudrick, Neil Salvage, Qais Sharif and Sam Zaid, consisting of all of the members of the Company’s Board of Directors (the “Board”), has resigned from the Board
the Company’s Senior Vice President and Chief Restructuring Officer, Mauricio Rivera, has resigned from his positions with the Company
each of Bruno Bowden, Jason Mudrick, Neil Salvage, Qais Sharif and Sam Zaid, consisting of all of the members of the Company’s Board of Directors (the “Board”), has resigned from the Board
each of Bruno Bowden, Jason Mudrick, Neil Salvage, Qais Sharif and Sam Zaid, consisting of all of the members of the Company’s Board of Directors (the “Board”), has resigned from the Board
the Board appointed Craig Jalbert, age 65, as the Company’s President, Treasurer and Corporate Secretary, and as the Company’s principal executive officer, principal financial officer and principal accounting officer
On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026.
Effective September 1, 2026, Mr. Sheng-Yih Chang resigned his position as Co-Chief Executive Officer and Chairman of the Board of the Company for health-related reasons.
On August 28, 2026, the Board of Directors appointed Mr. Kewei Huang, aka Kek Wee Ng, as Chief Executive Officer and Chairman of the Board of the Company, effective September 1, 2026.
On August 8, 2026, Aeternum entered into an employment agreement with Pieter Scholtz .as CFO of the Company.
On July 31, 2026, the Company entered into an employment agreement with Josua Oosthuizen .as CEO of the Company.
On August 28, 2026, Thomas J. Webb notified Otter Tail Corporation (the “Company”) of his intention to not stand for reelection and instead retire from the Company’s Board of Directors effective at the conclusion of his current term, which expires at the time of the 2027 Annual Meeting of Shareholders, in accordance with the Corporation’s director retirement policy.
On August 31, 2026, Kathryn O. Johnson notified the Company of her intention to not stand for reelection and instead retire from the Company’s Board of Directors effective at the conclusion of her current term, which expires at the time of the 2027 Annual Meeting of Shareholders, having reached retirement age in accordance with the Corporation’s director retirement policy.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
the sole director of Merger Sub immediately prior to the Effective Time became the sole director of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Charles Wagner.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
In connection with the consummation of the Merger, as of immediately after the Effective Time, Charles Wagner, Prasanna Thombre and Omar White became the President, Treasurer and Secretary of the Surviving Corporation, respectively.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
each of the directors of the Company, R. Scott Struthers, Ph.D., Camille L. Bedrosian, M.D., Caren Deardorf, Matthew K. Fust, Weston Nichols, Ph.D., Stephanie S. Okey, M.S., Rogério Vivaldi Coelho, M.D. and Wendell Wierenga, Ph.D., resigned and ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Certain officers of the Company, who resigned in their capacity as officers, but not employees, in connection with the Merger, immediately prior to the Effective Time were Ryan Hummer, Chief Executive Officer, Michael Morrison, Chief Financial Officer and Treasurer, Tim Willems, Chief Operations Officer, Ori Lev, Executive Vice President, General Counsel and Secretary and Dewayne Williams, Vice President and Controller.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
from and after the Effective Time, Beth Ann Dranguet became the sole director of the Company, and Beth Ann Dranguet, Depinder Sandhu, Maximiliano A. Kricorian, and Steven F. Carvalho became officers of the Company.
Certain officers of the Company, who resigned in their capacity as officers, but not employees, in connection with the Merger, immediately prior to the Effective Time were Ryan Hummer, Chief Executive Officer, Michael Morrison, Chief Financial Officer and Treasurer, Tim Willems, Chief Operations Officer, Ori Lev, Executive Vice President, General Counsel and Secretary and Dewayne Williams, Vice President and Controller.
Certain officers of the Company, who resigned in their capacity as officers, but not employees, in connection with the Merger, immediately prior to the Effective Time were Ryan Hummer, Chief Executive Officer, Michael Morrison, Chief Financial Officer and Treasurer, Tim Willems, Chief Operations Officer, Ori Lev, Executive Vice President, General Counsel and Secretary and Dewayne Williams, Vice President and Controller.
from and after the Effective Time, Beth Ann Dranguet became the sole director of the Company, and Beth Ann Dranguet, Depinder Sandhu, Maximiliano A. Kricorian, and Steven F. Carvalho became officers of the Company.
Certain officers of the Company, who resigned in their capacity as officers, but not employees, in connection with the Merger, immediately prior to the Effective Time were Ryan Hummer, Chief Executive Officer, Michael Morrison, Chief Financial Officer and Treasurer, Tim Willems, Chief Operations Officer, Ori Lev, Executive Vice President, General Counsel and Secretary and Dewayne Williams, Vice President and Controller.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
from and after the Effective Time, Beth Ann Dranguet became the sole director of the Company, and Beth Ann Dranguet, Depinder Sandhu, Maximiliano A. Kricorian, and Steven F. Carvalho became officers of the Company.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
from and after the Effective Time, Beth Ann Dranguet became the sole director of the Company, and Beth Ann Dranguet, Depinder Sandhu, Maximiliano A. Kricorian, and Steven F. Carvalho became officers of the Company.
from and after the Effective Time, Beth Ann Dranguet became the sole director of the Company, and Beth Ann Dranguet, Depinder Sandhu, Maximiliano A. Kricorian, and Steven F. Carvalho became officers of the Company.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
Certain officers of the Company, who resigned in their capacity as officers, but not employees, in connection with the Merger, immediately prior to the Effective Time were Ryan Hummer, Chief Executive Officer, Michael Morrison, Chief Financial Officer and Treasurer, Tim Willems, Chief Operations Officer, Ori Lev, Executive Vice President, General Counsel and Secretary and Dewayne Williams, Vice President and Controller.
Effective as of the Effective Time, in accordance with the Merger Agreement, each member of the Company’s board of directors and certain of the Company’s officers resigned from and ceased serving on the Company’s board of directors (including any committees thereof) and as officers of the Company, as applicable.
On August 30, 2026, the Board of Directors (the “Board”) of Invivyd, Inc. (the “Company”) appointed Marc Elia, Chairman of the Board, as the Company’s Chief Executive Officer, effective as of August 30, 2026
Mr. Elia will serve as the Company’s principal executive officer, a role previously held by William Duke, Jr., the Company’s Chief Financial Officer, who remains the Company’s principal financial officer and principal accounting officer.
the Board appointed Ajay Royan as the Lead Independent Director of the Board, effective as of the Effective Date.
On August 26, 2026, the Board appointed Shahin Behroyan as Chief Executive Officer of the Company, effective immediately.
On August 26, 2026, Katharyn Field informed the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) of her decision to transition from her role as Chief Executive Officer.
On August 27, 2026, Ryan M. Waymire accepted his appointment as Chief Merchandising Officer of the Company, effective September 28, 2026.
On August 31, 2026, Kohl’s Corporation (the “Company”) announced that Nick Jones, the Company’s Chief Merchandising Officer, will be departing the Company effective October 1, 2026.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.